Publicaciones en las que colabora con Juan Ignacio Arenas Mirave (40)

2021

  1. Clinical Characteristics and Outcome of Drug-Induced Liver Injury in the Older Patients: From the Young-Old to the Oldest-Old

    Clinical Pharmacology and Therapeutics, Vol. 109, Núm. 4, pp. 1147-1158

  2. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry

    Journal of Hepatology, Vol. 75, Núm. 1, pp. 86-97

2018

  1. Addition of granulocyte/monocyte apheresis to oral prednisone for steroid-dependent ulcerative colitis: A Randomized multicentre clinical trial

    Journal of Crohn's and Colitis, Vol. 12, Núm. 6, pp. 687-694

  2. Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry

    Clinical Gastroenterology and Hepatology, Vol. 16, Núm. 9, pp. 1495-1502

2015

  1. Decisiones terapéuticas en el tratamiento del carcinoma hepatocelular y patrones de uso de sorafenib. Resultados del estudio internacional observacional GIDEON en España

    Gastroenterologia y Hepatologia, Vol. 38, Núm. 4, pp. 263-273

2012

  1. Accurate fat fraction quantification by multiecho gradient-recalled-echo magnetic resonance at 1.5 T in rats with nonalcoholic fatty liver disease

    European Journal of Radiology, Vol. 81, Núm. 6, pp. 1122-1127

  2. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening

    New England Journal of Medicine, Vol. 366, Núm. 8, pp. 697-706

  3. Effect of neoadjuvant chemotherapy in hepatic steatosis

    Chemotherapy, Vol. 58, Núm. 2, pp. 89-94

  4. Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models

    Cancer Cell International, Vol. 12

2010

  1. Biochemical determination of lipid content in hepatic steatosis by the Soxtec method

    World Journal of Gastroenterology, Vol. 16, Núm. 12, pp. 1495-1499

  2. Colorectal cancer prognosis twenty years later

    World Journal of Gastroenterology, Vol. 16, Núm. 7, pp. 862-867

  3. Inflammatory mediators of hepatic steatosis

    Mediators of Inflammation, Vol. 2010

  4. Niveles plasmóticos de la vitamina B12 y ácido fólicoenpacientes con hepatopatía crónica

    Gastroenterologia y Hepatologia, Vol. 33, Núm. 4, pp. 280-287

2008

  1. Resveratrol inhibits nonalcoholic fatty liver disease in rats

    BMC Gastroenterology, Vol. 8

2007

  1. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants

    American Journal of Gastroenterology, Vol. 102, Núm. 3, pp. 507-515

  2. Levofloxacin-induced acute hepatitis

    Journal of Bronchology

  3. Low adherence to colonoscopy in the screening of first-degree relatives of patients with colorectal cancer

    Gut, Vol. 56, Núm. 12, pp. 1714-1718

  4. Selective sphincteroplasty of the papilla in cases at risk due to atypical anatomy

    World Journal of Gastroenterology, Vol. 13, Núm. 22, pp. 3106-3111

2006

  1. Consume moderado de alcohol y mortalidad por diversas causas

    Atencion Primaria

  2. Effect of resveratrol on alcohol-induced mortality and liver lesions in mice

    BMC Gastroenterology, Vol. 6